APR 1 9 2004 \$

FORM PTO-1449 (Modified)

Approved for use through 10/31/2002 SURE CITATION

US DEPARTMENT OF COMMERCE Docket No.
US Patent and Trademark Office

Docket No. 50623.352

Application No. 10/712,678

Applicant

Gene Michal

in an Application
(Use several sheets if necessary)

Filing Date

November 12, 2003

Group Art Unit 1615

				November 12, 2	003	1	615
		·	U.S. PAT	ENT DOCUMENTS		T	
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date If Appropriate
₹	A1	4,142,526	3/6/79	, Zaffaroni et al.	424	424	3/9/77
	A2	4,329,383	5/11/82	Joh	428	36	7/21/80
	А3	4,733,665	3/29/88	Palmaz	128	343	11/7/85
	A4	4,800,882	1/31/89	Gianturco	128	343	3/13/87
	A5	4,882,168	11/21/89	Casey et al.	424	468	9/5/86
-	A6	4,886,062	12/12/89	Wiktor	128	343	10/19/87
	A7	4,941,870	7/17/90	Okada et al.	- 600	36	12/30/88
	A8	4,977,901	12/18/90	Ofstead	128	772	4/6/90
	A9	5,112,457	5/12/92	Marchant	204	165	7/23/90
į÷.	A10	5,165,919	11/24/92	Sasaki et al.	424	488	9/26/90
	A11	5,272,012	12/21/93	Opolski	428	423.1	1/29/92
	A12	5,292,516	3/8/94	Viegas et al.	424	423	11/8/91
	A13	5,298,260	3/29/94	Viegas et al.	424	486	6/9/92
	A14	5,300,295	4/5/94	Viegas et al.	424	427	9/13/91
	A15	5,306,501	4/26/94	Viegas et al.	424	423	11/8/91
	A16	5,328,471	7/12/94	Slepian	604	101	8/4/93
	A17	5,330,768	7/19/94	Park et al.	424	501	7/5/91
	A18	5,380,299	1/10/95	Fearnot et al.	604	265	8/30/93
	A19	5,417,981	5/23/95	Endo et al.	424	486	4/28/93
	A20	5,447,724	9/5/95	Helmus et al.	424	426	11/15/93
*	A21	5,455,040	10/3/95	Marchant	424	426	11/19/92
	A22	5,462,990	10/31/95	Hubbell et al.	525	54.1	10/5/93
	A23	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93
	A24	5,569,463	10/29/96	Helmus et al.	424	426	6/7/95
	A25	5,578,073	11/26/96	Haimovich et al.	623	1	9/16/94
	A26	5,605,696	2/25/97	Eury et al.	424	423	3/30/95

<b>P</b> 2	A27	5,609,629	3/11/97	Fearnot et al.	623	1	6/7/95
	A28	5,624,411	4/29/97	Tuch	604	265	6/7/95
	A29	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
	A30	5,649,977	7/22/97	Campbell	623	1	9/22/94
	A31	5,658,995	8/19/97	Kohn et al.	525	432	11/27/95
	A32	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
	A33	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
	A34	5,679,400	10/21/97	Tuch	427	2.14	6/7/95
8-	A35	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
	A36	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
	A37	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A38	5,735,897	4/7/98	Buirge	623	12	1/2/97
	A39	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A40	5,776,184	7/7/98	Tuch	623	1	10/9/96
	A41	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
	A42	5,800,392	9/1/98	Racchini	604	96	5/8/96
	A43	5,820,917	10/13/98	Tuch	427	2.1	6/7/95
	A44	5,824,048	10/20/98	Tuch	623	1	10/9/96
	A45	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
	A46	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
	A47	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
	A48	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
e	A49	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97
	A50	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
	A51	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A52	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A53	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
	A54	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A55	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
	A56	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A57	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
	_ A58	5,971,954	10/26/99	Conway et al.	604	96	1/29/97

<b>A</b>	A59	5,980,928	11/9/99	Terry	424	427	7/29/97
1	A60	5,980,972	11/9/99	Ding <sup>-</sup>	427	2.24	9/22/97
• \	A61	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
	A62	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A63	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A64	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A65	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
	A66	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A67	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A68	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A69	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A70	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A71	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
-	A72	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A73	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A74	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A75	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A76	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A77	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
·	A78	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A79	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A80	6,129,761	10/10/00	Hubbell	623	11	6/7/95
	A81	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A82	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	A83	6,197,013	3/6/01	Reed et al.	604	509	11/6/96
	A84	6,200,337	3/13/01	Moriuchi et al.	623	1.16	11/18/98
	A85	6,203,551	3/20/01	Wu	. 606	108	10/4/99
	A86	6,206,916	3/27/01	Furst	623	1.46	7/29/99
	A87	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A88	6,240,616	6/5/01	Yan	29	527.2	4/15/97
コ	A89	6,245,753	6/12/01	Byun et al.	514	56	4/27/99

	A90	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
<u> </u>	-}				623	1.15	9/28/00
	A91	6,254,632	7/3/01	Wu et al.			
$\perp$	A92	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	A93	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
	A94	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
	A95	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	A96	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
	A97	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	A98	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
	A99	6,331,313	. 12/18/01	Wong et al.	424	427	10/22/99
1	A100	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
	A101	6,346,110	2/12/02	Wu	606	108	1/3/01
	A102	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
	A103	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A104	6,379,379	4/30/02	Wang	623	1.15	8/13/99
	A105	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
	A106	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
	A107	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
	A108	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A109	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
	A110	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
	A111	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
	A112	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A113	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A114	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A115	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A116	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A117	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
丁	_ A118	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00

G.	A119	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26	6/00
1	A120	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/	/01
	A121	6,572,644	6/3/03	Moein	623	1.11	6/27/	/01
	A122	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/	/00
	A123	6,585,926	7/1/03	Mirzaee	264	400	8/31/	/00
	A124	6,605,154	8/12/03	Villareal	118	500	5/31/	/01
		U.S. PATE	NT APPLICAT	ION PUBLICATION DOCUM	ENTS			*
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing D Approp	
B	A125	2001/0018469	8/30/01	Chen et al.	523	121	12/28	3/00
1	A126	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21/	/01
	A127	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/19	9/00
	A128	2002/0091433	7/11/02	Ding et al.	623	1.2	12/17	7/01
	A129	2002/0155212	10/24/02	Hossainy	427	2.25	4/24/	/01
	A130	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30/	/02
	A131	2003/0099712	5/29/03	Jayaraman	424	486	11/26	5/01
			FOREIGN PA	ATENT DOCUMENTS				
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Transla Yes	ation No
R	В1	EP 0 301 856 ·	2/1/89	European				
	B2	EP 0 514 406 ·	11/25/92	European				
	В3	EP 0 604 022	6/29/94	European			 	
	B4	EP 0 623 354 -	11/9/94	European	<u> </u>	\		
-	B5	EP 0 665 023 ·	8/2/95	European		<u> </u>		
	В6	EP 0 701 802 ·	3/20/96	European	ļ			
	B7	EP 0 716 836	6/19/96	European	ļ			
	B8	EP 0 809 999 ·	12/3/97	European		$\perp$		
	В9	EP 0 832 655	4/1/98	European				
	B10	EP 0 850 651	7/1/98	European		ļ		
	B11	EP 0 879 595 .	11/25/98	European	ļ			
	B12	EP 0 910 584 •	4/28/99	European	<u> </u>		<u> </u>	<b>\</b>
	B13	EP 0 923 953 '	6/23/99	European	ļ			1
	B14	EP 0 953 320 ·	11/3/99	European	<del> </del>			1
				European				

GP.	B16	EP 0 982 041 .	3/1/00	European			
<b>Q</b> Z	B17	EP 1 273 314 `	1/8/03	European			
Œ.	B18 .	2001-190687	7/17/01	Japan (Abstract)		Х	
\$	B19	WO 91/12846 -	9/5/91	PCT			
	B20	WO 95/10989	4/27/95	PCT			
	B21	WO 96/40174 ,	12/19/96	PCT			
	B22	WO 97/10011	3/20/97	PCT		·	
	B23	WO 97/45105 /	12/4/97	PCT			
	B24	WO 97/46590 ·	12/11/97	PCT			
	B25	WO 98/17331 `	4/30/98	PCT			
	B26	WO 98/36784 -	8/27/98	PCT ·	·		
	B27	WO 99/01118	1/14/99	PCT			
	B28	WO 99/38546	8/5/99	PCT			
	B29	WO 99/63981	12/16/99	PCT			
	B30	WO 00/02599 .	1/20/00	PCT			
	B31	WO 00/12147 -	3/9/00	PCT			
	B32	WO 00/18446 '	4/6/00	PCT		·	
	B33	WO 00/64506 *	11/2/00	PCT			
	B34	WO 01/01890	1/11/01	PCT			
	B35	WO 01/15751 \	3/8/01	PCT			
·	B36	WO 01/17577	3/15/01	PCT			
	B37	WO 01/45763 '	6/28/01	PCT			
	B38	WO 01/49338 ´	7/12/01	PCT			
	B39	WO 01/74414	10/11/01	PCT			
	B40	WO 02/03890 - \	1/17/02	PCT			
	B41	WO 02/026162 · ´	4/4/02	PCT			
	B42	WO 02/34311 <sup>-</sup>	5/2/02	PCT			
	B43	WO 02/056790 ·	7/25/02	PCT			
	B44	WO 03/000308	1/3/03	PCT			
	B45	WO 03/022323 <sup>·</sup>	3/20/03	PCT	·		
4	B46	WO 03/028780·	4/10/03	PCT			

P	B47	WO 03/037223 <sup>-</sup>	5/8/03	PCT				
P	B48	WO 03/039612 1	5/15/03	PCT				
		OTHER DO	CUMENTS (Inc	luding Author, Title, Date, Pertine	nt Pages, etc.)			
Tes	Anonymous, Cardiologists Draw - Up The Dream Stent, Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959, printed 8/25/03 (2 pages).							
	C2 <sub>.</sub>			complications by 30%, Clinica ht?req=1061847871753, printe			). 	
	C3 _	Anonymous, <i>Rolling</i> 1 (Abstract 434009), Re		Loading Device for Therapeut 4-975 (June 2000).	tic Agent Deliv	ery or Co	ated Ste	nt
	C4 _			inate cardiology, Clinica 720:2 ht?req=1061848017752, printe			·····	
	C5 _	Aoyagi et al., <i>Prepara</i> Journal of Controlled		d aliphatic polyester and applic (1994).	cation to therr	no-respor	sive ma	terial,
	C6 .	Barath et al., Low Dos Injury, JACC 13(2): 25		gents Prevents Smooth Muscle eb. 1989).	Cell Prolifera	ation After	Endothe	elial
-	C7 <sub>.</sub>	Barbucci et al., <i>Coatir</i> Mater. Res. 25:1259-		available materials with a new	v heparinizabi	le materia	l, J. Bion	ned.
	C8_	Chung et al., <i>Inner co</i> Journal of Controlled		n for drug delivery control of th 3 (2000).	ermo-respons	sive polym	neric mic	elles,
	C9 _			he Arterial Wall Via Polyuretha eterization and Cardiovascular				Stent:
	C10_	Dichek et al., Seeding 80(5):1347-1353 (Nov		Stents with Genetically Engine	ered Endothe	lial Cells,	Circ.	
				elivery from a Polymer Coated , JACC, 4A (701-1), Abstract (		1etallic Ste	ent: Kine	tics,
	C12.	Helmus, Overview of	Biomedical Mater	ials, MRS Bulletin, pp. 33-38 (S	Sept. 1991).	<del></del>		
	C13	Herdeg et al., Antiproliferative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Ca 3:197-199 (1998).					ent. Card	loit.
	C14	Inoue et al., An AB blo delivery of hydrophob	ock copolymer of o	oligo(methyl methacrylate) and of Controlled Release 51:221-2	l poly(acrylic a 229 (1998).	acid) for m	nicellar	
	C15 Kataoka et al., Block copolymer micelles as vehicles for drug delivery, Journal of Controlled Release 24:119-132 (1993).					Release		
	C16 Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).					mplants,		
	C17	Liu et al., <i>Drug releas</i> 68:167-174 (2000).	e characteristics o	of unimolecular polymeric mice	lles, Journal o	of Controll	ed Relea	ase
	C18 Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Bioma 18(12):885-890 (1997).					Biomater	rials	
17.		Matsumaru et al., <i>Em</i> Polymer Edn 8(7):555		r Endovascular Treatment of C	Cerebral Lesio	ns, J. Bio	mater. S	ci.
				anted Ethylene-Vinyl Alcohol C arcinoma and P388 Leukemia				(6)
1	. C21	Miyazawa et al., Effec Cardiovasc. Pharmac		nd Tranilast on Intimal Thicker 1997).	ning After Arte	erial Injury	in the R	at, J.

R	C23	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).				
	C23	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).				
	C24	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).				
	C25	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).				
		Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:68 694 (1996).				
		Shigeno, Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor, Chemical Abstract 125:212307 (1996).				
	+	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).				
		Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trends Cardiovasc. Med. 3(5):163-170 (1993).				
	C30	Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor, Journal of Controlled Release 50:79-92 (1998).				
EXAMINER		DATE CONSIDERED 09/30/2004				
		erences considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.  with next communication to applicant.				